Qiang Zhao, Xingfang Dou, H. Bai, Shuting Zhang, Yanping Han, Haiying Zhang, L. Fu, Jing Zhang, M. He
{"title":"Diffuse large B-cell lymphoma with thrombotic thrombocytopenic purpura: report of one case and review of literature","authors":"Qiang Zhao, Xingfang Dou, H. Bai, Shuting Zhang, Yanping Han, Haiying Zhang, L. Fu, Jing Zhang, M. He","doi":"10.3760/CMA.J.CN115356-20190620-00118","DOIUrl":null,"url":null,"abstract":"目的 \n探讨弥漫大B细胞淋巴瘤(DLBCL)合并血栓性血小板减少性紫癜(TTP)的临床表现与诊治要点。 \n \n \n方法 \n回顾分析联勤保障部队第九四○医院新诊断的1例DLBCL并发TTP患者的诊治过程,并进行文献复习。 \n \n \n结果 \n该患者首先确诊DLBCL,治疗缓解4年后血小板减少突然加剧,ADAMTS13活性严重缺乏,DLBCL合并TTP诊断成立,确诊后行输注新鲜冰冻血浆及激素治疗,治疗后病情明显好转。 \n \n \n结论 \nDLBCL并发TTP较为少见,可能是ADAMTS13活性严重缺乏导致血小板微血栓形成,一经确诊后进行血浆置换或输注冰冻血浆,可取得较好疗效。","PeriodicalId":16246,"journal":{"name":"白血病·淋巴瘤","volume":"29 1","pages":"187-189"},"PeriodicalIF":0.0000,"publicationDate":"2020-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"白血病·淋巴瘤","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.CN115356-20190620-00118","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
期刊介绍:
The JLL is a specialized academic journal that carries articles on hematological malignancies, and mainly about leukemia and lymphoma, involving the fields of medicine, chemistry, biology, etc. The purposes are to reflect the scientific results and the academic trends in the hematological malignancy field. It paid attention on both the basic research and clinical work, but more on the clinical side; on combining popularization with the raising of standards, but more on the raising of standards, in order to provide a field for exchanging experience, inspiring mutually and linking up information for those working for the basic research and clinical diagnosis and treatment in the field of leukemia and lymphoma. It is intended for high and middle ranking medical staffs.